Highlights
- The FDA awarded Vitalant $4,767,860.60 under contract 75F40119P10697 for an HIV risk questionnaire study.
- The study will assess the predictive value of a panel of questions for detecting recent HIV infection.
- Vitalant, headquartered in Scottsdale, is the sole named recipient of the Department of Health and Human Services award.
- No action date appears in the USAspending record; the award detail page is publicly accessible.
The Food and Drug Administration awarded Scottsdale-based Vitalant $4,767,860.60 under federal contract 75F40119P10697, according to USAspending.gov procurement records.
The contract funds what the award description calls an "HIV RISK QUESTIONNAIRE (HRQ) STUDY: AN ASSESSMENT OF THE PREDICTIVE VALUE OF A PANEL OF QUESTIONS FOR RECENT INFECTION WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV)." The place of performance is listed as Arizona.
The awarding agency is the Department of Health and Human Services, with the FDA as the component office. Vitalant is the sole named recipient. The USAspending record does not disclose a contract action date, competitive bidding details, or period of performance.
The full award record is available on the USAspending.gov detail page.
Sources
Every factual claim in this article traces to one of the sources below. See how we work for the editorial process.
- USAspending.gov retrieved 13/06/2026 03:18
- dnb.com retrieved 13/06/2026 03:18
Authored by The Scottsdale Signal. Drafted by AI from primary-source material under our beat-specific editorial guides; reviewed by humans before publish under our five-gate process. Sources retrieved at 13/06/2026 03:18. Every claim traces to a source.
